Loading
Latest filing published 10 Jan 2022 for T2 Biosystems, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Aparna Ahuja, listed as senior executive, appears in our data through filings on T2 Biosystems, Inc. shares, published by SEC (Form 4). In total, 2 filings cover trades dated from 5 January 2022 to 6 January 2022.
The open-market record consists of 1 sale, with no purchase. The totals do not cover 1 filing with an undisclosed amount. Outside the open market, there are 1 option exercise.
The newest entry dates from 10 January 2022: an open-market sale, in T2 Biosystems, Inc. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations